Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies ...
NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...
The RHEIA trial studied women with severe aortic stenosis and found that participants preferred transcatheter aortic valve replacement over surgical valve replacement.
Jenscare Scientific Co., Ltd. ('Jenscare' or the 'Company') (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR ...
Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement ... 5.3% of the control group (P=0.003); new permanent pacemakers were implanted in 17.4% and 2.3% ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Manufacturers are focused on developing miniaturized pacemakers to address the issue of patient comfort. Medtronic’s Micra Transcatheter Pacing System (TPS), the world’s smallest pacemaker, was ...